Defects_NNS in_IN interstrand_NN cross-link_NN uncoupling_VBG do_VBP not_RB account_VB for_IN the_DT extreme_JJ sensitivity_NN of_IN ERCC1_NP and_CC XPF_NP cells_NNS to_TO cisplatin_NN The_DT anticancer_NN drug_NN cisplatin_NN reacts_VBZ with_IN DNA_NP leading_VBG to_TO the_DT formation_NN of_IN interstrand_NN and_CC intrastrand_NN cross-links_NNS that_WDT are_VBP the_DT critical_JJ cytotoxic_JJ lesions_NNS ._SENT In_IN contrast_NN to_TO cells_NNS bearing_VBG mutations_NNS in_IN other_JJ components_NNS of_IN the_DT nucleotide_NN excision_NN repair_NN apparatus_NN (_( XPB_NP ,_, XPD_NP ,_, XPG_NP and_CC CSB_NP )_) ,_, cells_NNS defective_JJ for_IN the_DT ERCC1-XPF_NP structure-specific_JJ nuclease_NN are_VBP highly_RB sensitive_JJ to_TO cisplatin_NN ._SENT To_TO determine_VB if_IN the_DT extreme_JJ sensitivity_NN of_IN XPF_NP and_CC ERCC1_NP cells_NNS to_TO cisplatin_JJ results_NNS from_IN specific_JJ defects_NNS in_IN the_DT repair_NN of_IN either_DT intrastrand_NN or_CC interstrand_NN cross-links_NNS we_PP measured_VBD the_DT elimination_NN of_IN both_DT lesions_NNS in_IN a_DT range_NN of_IN nucleotide_NN excision_NN repair_NN Chinese_JJ hamster_NN mutant_JJ cell_NN lines_NNS ,_, including_VBG XPF-_NP and_CC ERCC1-defective_JJ cells_NNS ._SENT Compared_VBN to_TO the_DT parental_JJ ,_, repair-proficient_JJ cell_NN line_NN all_PDT the_DT mutants_NNS tested_VBN were_VBD defective_JJ in_IN the_DT elimination_NN of_IN both_DT classes_NNS of_IN adduct_VBP despite_IN their_PP$ very_JJ different_JJ levels_NNS of_IN increased_VBN sensitivity_NN ._SENT Consequently_RB ,_, there_EX is_VBZ no_DT clear_JJ relationship_NN between_IN initial_JJ incisions_NNS at_IN interstrand_NN cross-links_NNS or_CC removal_NN of_IN intrastrand_NN adducts_VBZ and_CC cellular_JJ sensitivity_NN ._SENT These_DT results_NNS demonstrate_VBP that_IN the_DT high_JJ cisplatin_NN sensitivity_NN of_IN ERCC1_NP and_CC XPF_NP cells_NNS likely_JJ results_NNS from_IN a_DT defect_NN other_JJ than_IN in_IN excision_NN repair_NN ._SENT In_IN contrast_NN to_TO other_JJ conventional_JJ DNA_NN cross-linking_NN agents_NNS ,_, we_PP found_VBD that_IN the_DT repair_NN of_IN cisplatin_NN adducts_VBZ does_VBZ not_RB involve_VB the_DT formation_NN of_IN DNA_NP double-strand_NN breaks_NNS ._SENT Surprisingly_RB ,_, XRCC2_NP and_CC XRCC3_NP cells_NNS are_VBP defective_JJ in_IN the_DT uncoupling_VBG step_NN of_IN cisplatin_JJ interstrand_NN cross-link_NN repair_NN ,_, suggesting_VBG that_IN homologous_JJ recombination_NN might_MD be_VB initiated_VBN prior_RB to_TO excision_NN of_IN this_DT type_NN of_IN cross-link_NN ._SENT The_DT anticancer_NN drug_NN cisplatin_NN reacts_VBZ with_IN the_DT N7_JJ atom_NN of_IN purine_NN bases_NNS and_CC forms_VBZ several_JJ types_NNS of_IN DNA_NP adduct_VBP ,_, including_VBG DNA_NP interstrand_NN cross-links_NNS (_( ICLs_NP )_) and_CC (_( 1,2-_CD and_CC 1,3-)intrastrand_JJ cross-links_NNS ._SENT Although_IN cisplatin_NN has_VBZ been_VBN widely_RB used_VBN in_IN cancer_NN chemotherapy_NN for_IN many_JJ years_NNS ,_, the_DT critical_JJ cytotoxic_JJ DNA_NN lesion_NN induced_VBN by_IN this_DT drug_NN is_VBZ still_RB debated_VBN ._SENT Evidence_NN that_IN both_DT 1,2-intrastrand_JJ cross-links_NNS and_CC ICLs_NNS are_VBP the_DT critical_JJ DNA_NN lesion_NN has_VBZ been_VBN presented_VBN ._SENT The_DT repair_NN of_IN cisplatin_NP intrastrand_NP adducts_VBZ has_VBZ been_VBN studied_VBN in_IN detail_NN using_VBG substrates_NNS containing_VBG defined_VBN site-specific_JJ cross-links_NNS ,_, and_CC cell_NN extracts_VBZ or_CC purified_VBN repair_NN proteins_NNS (_( --_: )_) ._SENT The_DT three_CD major_JJ cisplatin_NN intrastrand_NN cross-links_NNS ,_, 1,2-d(GpG)_JJ ,_, 1,2-d(ApG)_JJ and_CC 1,3d(GpNpG)_JJ ,_, are_VBP all_DT substrates_NNS for_IN the_DT mammalian_JJ nucleotide_NN excision_NN repair_NN (_( NER_JJ )_) apparatus_NN ._SENT The_DT 1,2-cisplatin_NN adducts_VBZ are_NN ,_, however_RB ,_, much_RB more_RBR poorly_RB recognised_VBN ,_, adding_VBG support_NN to_TO the_DT argument_NN that_IN they_PP are_VBP a_DT critical_JJ cytotoxic_JJ lesion_NN (_( ,_, )_) ._SENT The_DT less_RBR efficient_JJ repair_NN of_IN 1,2-intrastrand_NP adducts_VBZ is_VBZ believed_VBN to_TO result_VB from_IN the_DT smaller_JJR degree_NN of_IN helical_JJ distortion_NN these_DT cross-links_NNS induce_VB (_( ,_, )_) ._SENT In_IN contrast_NN ,_, very_RB little_RB is_VBZ known_VBN about_IN the_DT repair_NN of_IN cisplatin_NN ICLs_NNS ,_, which_WDT form_VBP between_IN guanines_NNS on_IN the_DT complementary_JJ DNA_NN strands_NNS ._SENT A_DT number_NN of_IN recent_JJ in_IN vitro_NN and_CC in_IN vivo_JJ studies_NNS indicate_VBP that_IN specialised_VBN repair_NN reactions_NNS might_MD incise_VB one_CD strand_NN of_IN the_DT cross-linked_JJ DNA_NN ,_, and_CC therefore_RB uncouple_VB the_DT ICLs_NNS formed_VBN by_IN the_DT nitrogen_NN mustard_NN mechlorethamine_NN and_CC those_DT induced_VBD following_VBG psoralen_NP plus_CC UVA_NP treatment_NN (_( ,_, )_) ,_, initiating_VBG repair_NN ._SENT These_DT reactions_NNS are_VBP dependent_JJ on_IN the_DT action_NN of_IN the_DT XPF_NP and_CC ERCC1_NP proteins_NNS ,_, but_CC not_RB other_JJ members_NNS of_IN the_DT mammalian_JJ NER_JJ apparatus_NN (_( --_: )_) ._SENT ERCC1_NP and_CC XPF_NP form_VBP a_DT tight_JJ heterodimeric_JJ complex_NN that_WDT possesses_VBZ endonuclease_NN activity_NN at_IN the_DT junctions_NNS between_IN single-stranded_JJ and_CC double-stranded_JJ DNA_NN ._SENT Two_CD different_JJ reactions_NNS have_VBP been_VBN described_VBN in_IN biochemical_JJ studies_NNS of_IN the_DT action_NN of_IN this_DT complex_NN on_IN DNA_NP containing_VBG defined_VBN ICLs_NNS ._SENT The_DT first_JJ reaction_NN involves_VBZ the_DT 3'->5_JJ '_POS degradation_NN of_IN the_DT DNA_NN surrounding_VBG the_DT ICL_NP on_IN one_CD strand_NN by_IN XPF_NP --_: ERCC1_NP (_( in_IN the_DT presence_NN of_IN RPA_NP )_) ,_, leaving_VBG a_DT single_NN uncoupled_VBD adducted_VBN nucleotide_NN attached_VBN to_TO the_DT complementary_JJ strand_NN ._SENT The_DT second_NN involves_VBZ incisions_NNS by_IN the_DT XPF_NP --_: ERCC1_JJ complex_NN 5_CD '_'' and_CC 3_CD '_'' to_TO the_DT ICL_NP ,_, uncoupling_VBG the_DT cross-link_NN ._SENT This_DT second_JJ reaction_NN requires_VBZ that_IN the_DT ICL_NP bears_VBZ an_DT unpaired_JJ region_NN located_VBN immediately_IN 3_CD '_'' to_TO the_DT ICL_NP and_CC it_PP was_VBD suggested_VBN that_IN such_JJ structures_NNS arise_VBP during_IN replication_NN and_CC contribute_VB to_TO ICL_NP repair_NN during_IN the_DT S_NP phase_NN of_IN the_DT cell_NN cycle_NN ._SENT Very_RB recently_RB it_PP has_VBZ been_VBN demonstrated_VBN that_IN human_JJ MutSbeta_NP might_MD be_VB involved_VBN in_IN the_DT recognition_NN and_CC uncoupling_VBG step_NN of_IN psoralen_NP ICL_NP repair_NN ._SENT Chinese_JJ hamster_NN ovary_NN (_( CHO_NP )_) cell_NN lines_NNS defective_JJ in_IN XPF_NP and_CC ERCC1_NP are_VBP extremely_RB sensitive_JJ to_TO cisplatin_NN (_( ,_, )_) ,_, in_IN contrast_NN to_TO cells_NNS defective_JJ in_IN other_JJ components_NNS of_IN the_DT NER_JJ apparatus_NN ._SENT For_IN agents_NNS such_JJ as_IN mechlorethamine_NP and_CC psoralen_NP plus_CC UVA_NP this_DT seems_VBZ likely_RB to_TO arise_VB ,_, at_IN least_JJS partly_RB ,_, from_IN an_DT inability_NN to_TO uncouple_VB the_DT ICLs_NNS produced_VBN by_IN these_DT agents_NNS by_IN the_DT pathways_NNS outlined_VBN above_IN (_( --_: )_) ._SENT However_RB ,_, another_DT possible_JJ explanation_NN is_VBZ that_IN ERCC1_NP and_CC XPF_NP cells_NNS are_VBP sensitive_JJ because_IN they_PP have_VBP a_DT dual_JJ defect_NN in_IN both_CC the_DT excision_NN repair_NN of_IN cross-links_NNS and_CC in_IN homologous_JJ recombination_NN ._SENT Homologous_JJ recombination_NN is_VBZ known_VBN to_TO be_VB an_DT important_JJ factor_NN determining_VBG survival_NN following_VBG treatment_NN with_IN cross-linking_JJ drugs_NNS ._SENT Importantly_RB ,_, the_DT Saccharomyces_NP cerevisiae_NN homologues_NNS of_IN XPF_NP and_CC ERCC1_NP (_( Rad1_NP and_CC Rad10_NP )_) are_VBP required_VBN for_IN the_DT single-strand_NN annealing_VBG subpathway_NN of_IN homologous_JJ recombination_NN and_CC there_EX is_VBZ now_RB good_JJ evidence_NN for_IN a_DT role_NN for_IN the_DT mammalian_JJ ERCC1_NN --_: XPF_NP complex_NN in_IN homology-driven_JJ recombination_NN (_( --_: )_) ._SENT We_PP sought_VBD to_TO understand_VB the_DT extreme_JJ sensitivity_NN of_IN mammalian_JJ XPF_NP and_CC ERCC1_NP cells_NNS to_TO cisplatin_NN ._SENT Measure_NN ments_NNS of_IN the_DT repair_NN capacity_NN for_IN the_DT two_CD candidate_NN critical_JJ lesions_NNS ,_, ICLs_NNS and_CC 1,2-intrastrand_JJ cross-links_NNS indicated_VBD that_IN ,_, although_IN both_DT are_VBP reduced_VBN in_IN XPF_NP and_CC ERCC1_NP cells_NNS ,_, these_DT processes_NNS were_VBD also_RB defective_JJ in_IN other_JJ NER_JJ mutants_NNS ._SENT Consequently_RB ,_, excision_NN repair_NN defects_NNS do_VBP not_RB seem_VB to_TO account_VB for_IN the_DT extreme_JJ sensitivity_NN of_IN ERCC1_NP and_CC XPF_NP cells_NNS to_TO cisplatin_NN ._SENT This_DT is_VBZ in_IN contrast_NN to_TO other_JJ cross-linking_NN agents_NNS such_JJ as_IN the_DT nitrogen_NN mustard_NN mechlorethamine_NN ,_, where_WRB specific_JJ defects_NNS in_IN ICL_NP uncoupling_VBG do_VBP appear_VB to_TO be_VB responsible_JJ for_IN the_DT sensitivity_NN of_IN ERCC1_NP and_CC XPF_NP cells_NNS ._SENT Cell_NN lines_NNS and_CC culture_NN conditions_NNS |_SYM The_DT cell_NN lines_NNS used_VBN in_IN this_DT study_NN are_VBP listed_VBN in_IN Table_NP ._SENT The_DT AA8_NP ,_, UV23_NP ,_, UV42_NP ,_, UV61_NP and_CC UV96_NP cell_NN lines_NNS were_VBD obtained_VBN from_IN Dr_NP M._NP Stefanini_NP (_( Istituto_NP di_NP Genetica_NP Biochimica_NP et_CC Evoluzionistica_NP ,_, Pavia_NP ,_, Italy_NP )_) ,_, while_IN UV135_NP was_VBD purchased_VBN from_IN the_DT American_NP Tissue_NP Culture_NP Collection_NP ._SENT The_DT V79_NP ,_, irs1_JJ ,_, irs1SF_NN ,_, CHO-K1_NP and_CC xrs5_JJ cell_NN lines_NNS were_VBD kindly_RB provided_VBN by_IN Prof._NP J._NP Thacker_NP (_( MRC_NP Radiation_NP and_CC Genome_NP Stability_NP Unit_NP ,_, Harwell_NP ,_, UK_NP )_) ._SENT All_DT cell_NN lines_NNS were_VBD grown_VBN as_IN monolayers_NNS in_IN F12_NP --_: Ham_NP HEPES_NP medium_NN (_( Sigma_NP ,_, Poole_NP ,_, UK_NP )_) supplemented_VBD with_IN 2_CD mM_NP glutamine_NN and_CC 10_CD %_NN foetal_JJ calf_NN serum_NN (_( FCS_NN )_) ._SENT Cells_NNS were_VBD grown_VBN at_IN 37C_JJ in_IN a_DT 5_CD %_NN CO2_JJ incubator_NN ._SENT Trypsin_NN /versine_NN solution_NN was_VBD used_VBN to_TO detach_VB cells_NNS ._SENT Chemicals_NNS and_CC enzymes_NNS |_SYM Cisplatin_NP (_( 100_CD mg_NN /100_CD ml_NN injectable_JJ aqueous_JJ stock_NN solution_NN containing_VBG 900_CD mg_NN /100_CD ml_NN sodium_NN chloride_NN and_CC 100_CD mg_NN /100_CD ml_NN mannitol_NN )_) was_VBD obtained_VBN from_IN David_NP Bull_NP Laboratories_NPS (_( Australia_NP )_) ._SENT Analytical_NP grade_NN mechlorethamine_NN (_( nitrogen_NN mustard_NN or_CC HN2_NP )_) was_VBD purchased_VBN from_IN Sigma_NP ._SENT All_DT enzymes_NNS used_VBN were_VBD purchased_VBN from_IN Promega_NP UK_NP ._SENT Cytotoxicity_JJ assay_NN |_SYM Cytotoxicity_NN was_VBD determined_VBN using_VBG the_DT SRB_NP growth_NN inhibition_NN assay_NN ,_, described_VBN in_IN detail_NN previously_RB ._SENT Determination_NN of_IN DNA_NP interstrand_NN cross-linking_NN using_VBG the_DT Comet_JJ assay_NN |_SYM This_DT was_VBD determined_VBN using_VBG a_DT modification_NN of_IN the_DT Comet_NP assay_NN (_( ,_, )_) ._SENT Exponentially_RB growing_VBG cells_NNS were_VBD treated_VBN with_IN the_DT desired_VBN concentrations_NNS of_IN cisplatin_NN in_IN FCS-free_JJ medium_NN for_IN 1_CD h_NN at_IN 37C_JJ to_TO reduce_VB binding_VBG to_TO serum_NN protein_NN ._SENT The_DT medium_NN was_VBD replaced_VBN with_IN fresh_JJ complete_JJ medium_NN and_CC incubation_NN continued_VBN for_IN the_DT required_JJ post-incubation_NN time_NN ._SENT Cells_NNS were_VBD then_RB trypsinised_VBN and_CC diluted_VBN to_TO a_DT density_NN of_IN 2.5_CD x_NN 104_CD cells_NNS /ml_NN and_CC kept_VBD on_IN ice_NN ._SENT All_DT drug-treated_JJ samples_NNS ,_, plus_CC one_CD control_NN ,_, were_VBD subjected_VBN to_TO 12.5_CD Gy_NN X-irradiation_NN on_IN ice_NN ,_, and_CC an_DT unirradiated_JJ control_NN was_VBD included_VBN ._SENT Microscope_NN slides_NNS were_VBD pre-coated_JJ with_IN 1_CD %_NN (_( w_NN /v_NN )_) Type-IA_NP agarose_NN and_CC 0.5_CD ml_NN of_IN cells_NNS were_VBD mixed_VBN with_IN 1_CD ml_NN of_IN 1_CD %_NN (_( w_NN /v_NN )_) Type-VII_NP agarose_NN and_CC spread_NN over_IN a_DT pre-coated_JJ slide_NN in_IN duplicate_NN ._SENT A_DT coverslip_NN was_VBD added_VBN and_CC the_DT agarose_NN was_VBD allowed_VBN to_TO solidify_VB ._SENT The_DT coverslips_NNS were_VBD removed_VBN and_CC the_DT slides_NNS were_VBD placed_VBN in_IN lysis_NN solution_NN (_( 100_CD mM_NP Na2EDTA_NP ,_, 2.5_CD M_NP NaCl_NP ,_, 10_CD mM_NP Tris_NP --_: HCl_NP ,_, pH_NN 10.5_CD )_) containing_VBG 1_CD %_NN Triton_NP X-100_NP at_IN 4C_JJ and_CC incubated_VBN for_IN 1_CD h_NN in_IN the_DT dark_NN ._SENT The_DT slides_NNS were_VBD subsequently_RB washed_VBN with_IN ice-cold_JJ water_NN for_IN 15_CD min_NN and_CC this_DT was_VBD repeated_VBN three_CD times_NNS ._SENT The_DT slides_NNS were_VBD then_RB transferred_VBN to_TO an_DT electrophoresis_NN tank_NN containing_VBG ice-cold_JJ alkaline_JJ solution_NN (_( 50_CD mM_NP NaOH_NP ,_, 1_CD mM_NP Na2EDTA_NP ,_, pH_NN 12.5_CD )_) and_CC incubated_VBN for_IN 45_CD min_NN in_IN the_DT dark_NN ._SENT Electrophoresis_NN was_VBD carried_VBN out_RP for_IN 25_CD min_NN at_IN 18_CD V_CD (_( 0.6_CD V_CD /cm_NN )_) ,_, 250_CD mA_NNS in_IN the_DT dark_NN ._SENT Slides_NNS were_VBD removed_VBN and_CC 1_CD ml_NN of_IN neutralising_VBG solution_NN (_( 0.5_CD M_NP Tris_NP --_: HCl_NP ,_, pH_NN 7.5_CD )_) was_VBD added_VBN and_CC incubated_VBN for_IN 10_CD min_NN ._SENT Each_DT slide_NN was_VBD rinsed_VBN twice_RB with_IN 1_CD ml_NN of_IN phosphate-buffered_JJ saline_NN (_( PBS_NP )_) and_CC allowed_VBN to_TO dry_VB overnight_RB at_IN room_NN temperature_NN ._SENT Slides_NNS were_VBD stained_VBN with_IN 2.5_CD microg_NN /ml_NN propidium_NN iodide_NN and_CC comets_NNS were_VBD analysed_VBN using_VBG a_DT Nikon_NP DIAPHOT_NP TDM_NP inverted_VBD epifluorescent_JJ microscope_NN (_( consisting_VBG of_IN a_DT high_JJ pressure_NN mercury_NN vapour_NN light_JJ source_NN ,_, a_DT 580_CD nm_NN dichroic_JJ mirror_NN ,_, a_DT 510_CD --_: 560_CD nm_NN excitation_NN filter_NN and_CC a_DT 590_CD nm_NN barrier_NN filter_NN )_) at_IN 20x_JJ magnification_NN ._SENT Fifty_CD cells_NNS were_VBD analysed_VBN per_IN slide_NN using_VBG Komet_NP Assay_NP Software_NP (_( Kinetic_NP Imaging_NP ,_, Liverpool_NP ,_, UK_NP )_) ._SENT The_DT degree_NN of_IN DNA_NN interstrand_NN cross-linking_VBG present_JJ in_IN a_DT drug-treated_JJ sample_NN was_VBD determined_VBN by_IN comparing_VBG the_DT tail_JJ moment_NN of_IN the_DT irradiated_JJ drug-treated_JJ samples_NNS with_IN irradiated_JJ untreated_JJ samples_NNS and_CC unirradiated_JJ untreated_JJ samples_NNS ._SENT The_DT level_NN of_IN interstrand_NN cross-linking_NN is_VBZ proportional_JJ to_TO the_DT decrease_NN in_IN tail_JJ moment_NN (_( DTM_NP )_) in_IN the_DT irradiated_JJ drug-treated_JJ sample_NN compared_VBN to_TO the_DT irradiated_JJ untreated_JJ control_NN ._SENT The_DT DTM_NP is_VBZ calculated_VBN by_IN the_DT following_VBG formula_NN :_: %_NN DTM_NP =_SYM [_SYM 1_CD --_: (_( TMdi_NP --_: TMcu_NP )_) /(TMci_NN --_: TMcu_NP )_) ]_SYM x_SYM 100_CD where_WRB TMdi_NP is_VBZ the_DT mean_JJ tail_NN moment_NN of_IN the_DT drug-treated_JJ ,_, irradiated_JJ sample_NN ,_, TMci_NP is_VBZ the_DT mean_JJ tail_NN moment_NN of_IN the_DT irradiated_JJ control_NN sample_NN and_CC TMcu_NP is_VBZ the_DT mean_JJ tail_NN moment_NN of_IN the_DT unirradiated_JJ control_NN sample_NN ._SENT Measurement_NN of_IN cisplatin_JJ intrastrand_NN cross-links_NNS by_IN ELISA_NP |_SYM Exponentially_RB growing_VBG cells_NNS were_VBD treated_VBN with_IN cisplatin_NN for_IN 1_CD h_NN and_CC incubated_VBN in_IN drug-free_JJ medium_NN for_IN various_JJ times_NNS or_CC assayed_VBD immediately_RB ._SENT Cells_NNS were_VBD washed_VBN with_IN PBS_NP twices_JJ and_CC genomic_JJ DNA_NN was_VBD isolated_VBN using_VBG a_DT Qiagen_NP Genomic_NP DNA_NP Tip_NP ._SENT Genomic_NP DNA_NP was_VBD digested_VBN with_IN HindIII_NP ,_, ethanol_NN precipitated_VBD and_CC resuspended_VBD in_IN water_NN ._SENT The_DT DNA_NP concentration_NN was_VBD determined_VBN fluorimetrically_RB ._SENT The_DT competitive_JJ ELISA_NN developed_VBN by_IN Tilby_NP et_FW al._FW (_( ,_, )_) was_VBD used_VBN with_IN certain_JJ modifications_NNS ._SENT ELISA_NP plates_NNS (_( high-bind_NN 96-well_NN flat_JJ bottom_NN ;_: Greiner_NP )_) were_VBD prepared_VBN the_DT day_NN before_IN by_IN coating_VBG the_DT wells_NNS with_IN platinated_JJ DNA_NN ._SENT Denatured_VBN calf_NN thymus_NN DNA_NN treated_VBN with_IN cisplatin_NN to_TO give_VB an_DT adduct_VBP level_NN of_IN 35.2_CD microM_NN /g_NN DNA_NN (_( provided_VBN by_IN M._NP J._NP Tilby_NP ,_, University_NP of_IN Newcastle_NP ,_, UK_NP )_) was_VBD diluted_VBN 1:2000_CD in_IN coating_NN buffer_NN (_( 1_CD M_NP sodium_NN chloride_NN ,_, 50_CD mM_NP sodium_NN phosphate_NN ,_, 0.02_CD %_NN sodium_NN azide_NN )_) and_CC 50_CD microl_NN of_IN this_DT solution_NN was_VBD incubated_VBN in_IN each_DT well_NN at_IN 37C_JJ overnight_JJ ._SENT ELISA_NP wells_NNS were_VBD then_RB blocked_VBN with_IN 150_CD microl_NN /well_NP BSA_NP solution_NN (_( 1_CD %_NN w_NN /v_NN in_IN PBS_NP )_) for_IN at_IN least_JJS 30_CD min_NN at_IN room_NN temperature_NN ._SENT Assay_NN samples_NNS and_CC the_DT standard_JJ (_( kindly_RB provided_VBN by_IN M._NP J._NP Tilby_NP )_) were_VBD incubated_VBN in_IN boiling_VBG water_NN for_IN 5_CD min_NN to_TO increase_VB immunoreactivity_NN and_CC serially_RB diluted_VBN in_IN DB_NP buffer_NN (_( 50_CD mM_NP sodium_NN chloride_NN ,_, 50_CD mM_NP sodium_NN phosphate_NN ,_, pH_NN 7.0_CD )_) ._SENT ICR4_JJ antibody_NN was_VBD diluted_VBN 1:60_CD 000_CD in_IN PBS_NP containing_VBG 0.2_CD %_NN BSA_NP ,_, 90_CD mM_NP sodium_NN chloride_NN ,_, 0.2_CD %_NN Tween-20_NP and_CC 0.2_CD mg_NN /ml_NN phenol_NN red_NN and_CC 55_CD microl_NN of_IN this_DT solution_NN was_VBD mixed_VBN with_IN 55_CD microl_NN of_IN serially_RB diluted_VBN assay_NN samples_NNS and_CC the_DT standard_NN ._SENT After_IN 30_CD min_NN incubation_NN at_IN 37C_JJ ,_, 50_CD microl_NN aliquots_NNS were_VBD transferred_VBN to_TO coated_JJ 96-well_NP ELISA_NP plates_NNS and_CC incubated_VBN for_IN 1_CD h_NN at_IN 37C_JJ ._SENT All_DT samples_NNS were_VBD assayed_VBN in_IN duplicate_NN ._SENT Each_DT assay_NN plate_NN included_VBD wells_NNS without_IN sample_NN (_( only_JJ antibody_NN )_) and_CC wells_NNS without_IN antibody_NN (_( only_JJ sample_NN /standard_NN )_) ._SENT Following_VBG five_CD washes_VBZ with_IN PBS_NP containing_VBG 0.1_CD %_NN (_( v_NN /v_NN )_) Tween-20_NP ,_, bound_JJ antibody_NN was_VBD determined_VBN using_VBG 50_CD microl_NN /well_NN biotinylated_JJ goat_NN anti-rat_NN antibody_NN (_( Sigma_NP )_) diluted_VBD 1:2500_CD in_IN PBS_NP containing_VBG 1_CD %_NN BSA_NP ,_, 0.2_CD %_NN Tween-20_NP ._SENT Following_VBG 30_CD min_NN incubation_NN at_IN 37C_JJ ,_, plates_NNS were_VBD washed_VBN three_CD times_NNS with_IN PBS_NP containing_VBG 0.1_CD %_NN (_( v_NN /v_NN )_) Tween-20_NP and_CC wells_NNS were_VBD incubated_VBN with_IN 50_CD microl_NN of_IN streptavidin_NN --_: beta-galactosidase_NN reagent_NN (_( Boehringer_NP )_) (_( stock_NN dissolved_VBN in_IN 1_CD ml_NN of_IN PBS_NP and_CC diluted_VBN 1:10_CD 000_CD in_IN PBS_NP containing_VBG 10_CD mM_NP MgCl2_NP ,_, 1_CD %_NN BSA_NP and_CC 0.1_CD %_NN Tween-20_NN )_) ._SENT Following_VBG 30_CD min_NN incubation_NN at_IN 37C_JJ ,_, plates_NNS were_VBD washed_VBN seven_CD times_NNS and_CC incubated_VBN with_IN 50_CD microl_NN /well_NN 4-methyl-umbelliferyl_JJ beta-d-galactoside_NN (_( Sigma_NP )_) (_( 80_CD microg_NN /ml_NN solution_NN made_VBN in_IN PBS_NP containing_VBG 10_CD mM_NP MgCl2_NP and_CC azide_NN )_) ._SENT Plates_NNS were_VBD covered_VBN and_CC placed_VBN in_IN the_DT dark_NN for_IN 2_CD --_: 4_CD h._NN To_TO measure_VB the_DT fluorescence_NN of_IN each_DT well_NN ,_, plates_NNS were_VBD read_VBN at_IN 360_CD nm_NN emission_NN and_CC 465_CD nm_NN excitation_NN using_VBG a_DT Tecan_NP Spectrafluor_NP Plus_NP plate_NN reader_NN ._SENT The_DT mean_JJ background_NN reading_NN was_VBD subtracted_VBN from_IN all_PDT the_DT readings_NNS and_CC the_DT percentage_NN inhibition_NN of_IN maximum_JJ fluorescence_NN was_VBD calculated_VBN for_IN each_DT serial_JJ dilution_NN of_IN the_DT assay_NN samples_NNS and_CC the_DT standard_NN ._SENT Cisplatin_NP intrastrand_NP adduct_VBP levels_NNS were_VBD then_RB calculated_VBN as_IN described_VBN by_IN Tilby_NP et_FW al._FW ._SENT Analysis_NN of_IN double-strand_NN breaks_NNS (_( DSBs_NP )_) by_IN pulsed_VBN field_NN gel_NN electrophoresis_NN (_( PFGE_NP )_) |_SYM Cells_NP growing_VBG in_IN a_DT monolayer_NN were_VBD treated_VBN with_IN cisplatin_NN for_IN 1_CD h_NN ,_, washed_VBN with_IN 10_CD ml_NN of_IN PBS_NP and_CC incubated_VBN with_IN fresh_JJ medium_NN for_IN the_DT required_JJ repair_NN time_NN ._SENT Cells_NNS were_VBD trypsinised_VBN ,_, 3_CD x_SYM 106_CD cells_NNS were_VBD harvested_VBN and_CC PFGE_JJ plugs_NNS were_VBD prepared_VBN using_VBG the_DT Bio-Rad_NP Mammalian_NP CHEF_NP Genomic_NP Plug_NP Kit_NP ,_, as_RB instructed_VBN by_IN the_DT manufacturer_NN ._SENT PFGE_NP was_VBD performed_VBN with_IN a_DT 0.7_CD %_NN gel_NN (_( Pulse_NP Field_NP Certified_NP Agarose_NP ;_: Bio-Rad_NP )_) in_IN 0.25x_NP TBE_NP buffer_NN using_VBG a_DT Biometra_NP Rotaphor_NP Type_NP V_CD apparatus_NN ._SENT Electrophoresis_NN runs_NNS were_VBD for_IN 120_CD h_NN at_IN 14C_NP with_IN the_DT following_VBG parameters_NNS :_: interval_NN 5000_CD --_: 1000_CD s_NN log_NN ,_, angle_NN 110_CD --_: 100_CD linear_JJ ,_, voltage_NN 50_CD --_: 45_CD V_CD linear_JJ ._SENT On_IN completion_NN the_DT gels_NNS were_VBD stained_VBN with_IN 2_CD microg_NN /ml_NN ethidium_NN bromide_NN for_IN 1_CD h_NN ,_, destained_VBN overnight_RB with_IN water_NN and_CC photographed_VBN ._SENT Semi-quantitative_JJ data_NNS were_VBD obtained_VBN by_IN measuring_VBG the_DT absolute_JJ integrated_JJ optical_JJ density_NN of_IN each_DT lane_NN using_VBG Gel_NP Pro_NP Analyser_NP (_( Media_NP Cybernetics_NP )_) and_CC calculating_VBG the_DT percentage_NN of_IN DNA_NN released_VBN from_IN the_DT DNA_NP plug_NN ._SENT Table_NP 1_CD |_SYM Chinese_JJ hamster_NN cell_NN lines_NNS used_VBN in_IN this_DT study_NN ERCC1_NP and_CC XPF_NP cells_NNS are_VBP highly_RB sensitive_JJ to_TO cisplatin_NN |_SYM Exponentially_RB growing_VBG cells_NNS were_VBD treated_VBN with_IN increasing_VBG concentrations_NNS of_IN cisplatin_NN for_IN 1_CD h_NN and_CC growth_NN inhibition_NN measured_VBD using_VBG the_DT SRB_NP assay_NN ._SENT As_IN shown_VBN in_IN Figure_NP ,_, the_DT UV47_JJ and_CC UV96_JJ cell_NN lines_NNS ,_, defective_JJ in_IN XPF_NP and_CC ERCC1_NP ,_, respectively_RB ,_, showed_VBD extreme_JJ sensitivity_NN to_TO cisplatin_NNS compared_VBN to_TO their_PP$ isogenic_JJ parent_NN cell_NN line_NN AA8_NP ._SENT When_WRB IC50_NP values_NNS were_VBD compared_VBN ,_, XPF_NP and_CC ERCC1_NP mutants_NNS were_VBD 40-_CD and_CC 37-fold_JJ more_JJR sensitive_JJ to_TO cisplatin_NN than_IN their_PP$ parent_NN cell_NN line_NN ,_, indicating_VBG the_DT crucial_JJ role_NN of_IN this_DT structure-specific_JJ nuclease_NN in_IN the_DT repair_NN of_IN cisplatin-induced_JJ DNA_NN damage_NN ._SENT In_IN contrast_NN ,_, the_DT XPB_NP ,_, XPD_NP and_CC XPG_NP mutant_JJ cells_NNS were_VBD only_RB 1.4-_CD ,_, 1.3-_CD and_CC 3.1-fold_JJ more_JJR sensitive_JJ than_IN the_DT parent_NN cell_NN line_NN ,_, respectively_RB ,_, suggesting_VBG a_DT minor_JJ role_NN for_IN these_DT NER_JJ proteins_NNS in_IN the_DT response_NN to_TO critical_JJ cisplatin_NN lesions_NNS ._SENT Induction_NN and_CC repair_NN of_IN DNA_NP ICLs_NP |_SYM DNA_NN ICLs_NNS are_VBP a_DT potentially_RB cytotoxic_JJ ,_, but_CC quantitatively_RB minor_JJ ,_, adduct_VBP (_( similar1_JJ %_NN of_IN the_DT total_JJ lesions_NNS )_) formed_VBN by_IN cisplatin_NN ._SENT Using_VBG a_DT modification_NN of_IN the_DT Comet_NP assay_NN ,_, which_WDT permits_VBZ detection_NN of_IN ICLs_NNS at_IN the_DT single_JJ cell_NN level_NN in_IN vivo_RB ,_, the_DT induction_NN and_CC repair_NN kinetics_NNS of_IN cisplatin-induced_JJ ICLs_NNS were_VBD studied_VBN ._SENT Prior_RB to_TO cell_NN lysis_NN the_DT cells_NNS receive_VBP a_DT fixed_VBN dose_NN of_IN X-rays_NNS to_TO induce_VB random_JJ strand_NN breakage_NN ._SENT The_DT presence_NN of_IN ICLs_NP retards_VBZ migration_NN of_IN the_DT irradiated_JJ DNA_NN during_IN electrophoresis_NN ,_, resulting_VBG in_IN a_DT reduced_VBN tail_NN moment_NN compared_VBN to_TO the_DT non-drug-treated_JJ control_NN ._SENT Figure_NP A_NP shows_VBZ the_DT percentage_NN decrease_NN in_IN tail_JJ moment_NN with_IN increasing_VBG concentrations_NNS of_IN cisplatin_NN for_IN the_DT parental_JJ ,_, repair-proficient_JJ AA8_NP cell_NN line_NN ._SENT A_DT decrease_NN in_IN tail_JJ moment_NN occurs_VBZ linearly_RB up_RB to_TO 30_CD microM_NN ,_, but_CC no_RB further_RBR significant_JJ increase_NN was_VBD observed_VBN at_IN 50_CD microM_NN ._SENT No_DT single-strand_NN breaks_NNS were_VBD seen_VBN in_IN unirradiated_JJ samples_NNS treated_VBN with_IN increasing_VBG doses_NNS of_IN cisplatin_NN (_( data_NNS not_RB shown_VBN )_) ._SENT The_DT kinetics_NN of_IN ICL_NP induction_NN and_CC repair_NN in_IN the_DT NER_JJ mutants_NNS were_VBD examined_VBN following_VBG a_DT 1_CD h_NN treatment_NN with_IN 50_CD microM_NN cisplatin_NN (_( Fig._NN B_NN )_) ._SENT This_DT dose_NN gives_VBZ 50_CD %_NN inhibition_NN of_IN growth_NN in_IN AA8_NP cells_NNS and_CC induces_VBZ a_DT readily_RB detectable_JJ level_NN of_IN ICLs_NP (_( similar40_JJ %_NN decrease_NN in_IN tail_JJ moment_NN )_) ._SENT As_IN previously_RB reported_VBN ,_, ICL_NP levels_NNS peak_NN at_IN similar8_JJ h_NN ,_, followed_VBN by_IN gradual_JJ repair_NN that_WDT is_VBZ still_RB incomplete_JJ at_IN 72_CD h_NN post-treatment_JJ incubation_NN ._SENT AA8_NP and_CC its_PP$ isogenic_JJ NER_JJ mutant_JJ derivatives_NNS (_( XPB_NP ,_, XPG_NP ,_, XPF_NP and_CC ERCC1_NP )_) were_VBD treated_VBN with_IN 50_CD microM_NN cisplatin_NN for_IN 1_CD h_NN and_CC the_DT level_NN of_IN ICLs_NP assessed_VBD following_VBG 0_CD ,_, 24_CD ,_, 48_CD and_CC 72_CD h_NN post-incubation_NN in_IN drug-free_JJ medium_NN (_( Fig._NN C_NP )_) ._SENT A_DT comparable_JJ level_NN of_IN ICLs_NP was_VBD observed_VBN in_IN all_PDT these_DT cell_NN lines_NNS immediately_RB following_VBG the_DT 1_CD h_NN treatment_NN ,_, demonstrating_VBG that_IN the_DT differences_NNS in_IN sensitivity_NN are_VBP not_RB due_JJ to_TO differences_NNS in_IN the_DT induction_NN of_IN ICLs_NP ._SENT Consistent_JJ with_IN their_PP$ extreme_JJ sensitivities_NNS ,_, the_DT XPF_NP and_CC ERCC1_NP mutants_NNS were_VBD defective_JJ in_IN the_DT uncoupling_VBG step_NN ,_, or_CC incision_NN ,_, of_IN cisplatin-induced_JJ ICLs_NNS ._SENT Surprisingly_RB ,_, the_DT much_RB less_RBR sensitive_JJ XPB_NP and_CC XPG_NP mutants_NNS were_VBD also_RB defective_JJ in_IN the_DT uncoupling_VBG of_IN ICLs_NP ._SENT The_DT lack_NN of_IN correlation_NN between_IN sensitivity_NN to_TO cisplatin_NN and_CC ICL_NP incision_NN capacity_NN implies_VBZ that_IN the_DT differential_JJ sensitivities_NNS of_IN the_DT NER_JJ mutants_NNS to_TO cisplatin_NN are_VBP not_RB due_JJ to_TO a_DT difference_NN in_IN their_PP$ ability_NN to_TO initiate_VB repair_NN of_IN the_DT ICLs_NNS induced_VBN by_IN this_DT drug_NN ._SENT Induction_NN and_CC repair_NN of_IN cisplatin_JJ 1,2-intrastrand_JJ cross-links_NNS |_SYM Since_IN no_DT definite_JJ correlation_NN was_VBD observed_VBN between_IN cisplatin_JJ sensitivity_NN and_CC the_DT uncoupling_VBG of_IN ICLs_NNS in_IN any_DT of_IN the_DT NER_JJ mutants_NNS ,_, the_DT induction_NN and_CC repair_NN of_IN intrastrand_NP cisplatin_NP adducts_VBZ was_VBD investigated_VBN in_IN the_DT parent_NN and_CC NER_JJ mutant_JJ cell_NN lines_NNS ._SENT These_DT adducts_VBZ were_VBD measured_VBN using_VBG a_DT competitive_JJ ELISA_NP method_NN developed_VBN by_IN Tilby_NP et_FW al._FW employing_VBG a_DT monoclonal_NN antibody_NN which_WDT recognises_VBZ cisplatin_JJ 1,2-intrastrand_JJ cross-links_NNS (_( ;_: M.Tilby_NP ,_, personal_JJ communication_NN )_) ._SENT In_IN Figure_NP A_NP ,_, the_DT AA8_NP parental_JJ cell_NN line_NN was_VBD treated_VBN with_IN increasing_VBG doses_NNS of_IN cisplatin_NN for_IN 1_CD h_NN and_CC a_DT linear_JJ increase_NN in_IN the_DT induction_NN of_IN cisplatin_NP intrastrand_NP adducts_VBZ was_VBD observed_VBN ._SENT In_IN subsequent_JJ experiments_NNS 50_CD microM_NN cisplatin_NN ,_, the_DT IC50_NP value_NN in_IN the_DT AA8_NP parent_NN cell_NN line_NN ,_, was_VBD used_VBN as_IN it_PP gave_VBD a_DT readily_RB measurable_JJ level_NN of_IN adducts_VBZ (_( 9.5_CD fmol/microg_NN DNA_NN )_) ._SENT The_DT repair_NN kinetics_NN of_IN cisplatin_JJ intrastrand_NN cross-links_NNS in_IN the_DT AA8_NP parent_NN cell_NN line_NN are_VBP shown_VBN in_IN Figure_NP B._NP Following_VBG a_DT 1_CD h_NN drug_NN treatment_NN ,_, the_DT level_NN of_IN intrastrand_NN adducts_VBZ peaked_VBN after_IN 4_CD h_NN post-treatment_JJ incubation_NN ,_, consistent_JJ with_IN previous_JJ reports_NNS ._SENT At_IN 24_CD and_CC 48_CD h_NN following_VBG drug_NN removal_NN 64_CD and_CC 74_CD %_NN of_IN the_DT adducts_VBZ were_VBD eliminated_VBN ,_, respectively_RB ._SENT Figure_NN shows_VBZ the_DT post-treatment_JJ elimination_NN of_IN cisplatin_JJ 1,2-intrastrand_JJ cross-links_NNS in_IN the_DT NER_JJ mutants_NNS ._SENT The_DT XPG_NP mutant_NN was_VBD most_RBS severely_RB defective_JJ in_IN the_DT elimination_NN of_IN these_DT adducts_VBZ ._SENT At_IN 48_CD h_NN following_VBG drug_NN removal_NN ,_, 3.7_CD times_NNS more_JJR intrastrand_NN adduct_VB remained_VBN in_IN the_DT XPG-defective_JJ cells_NNS than_IN the_DT parent_NN cell_NN line_NN ._SENT The_DT XPF_NP and_CC ERCC1_NP mutants_NNS were_VBD also_RB defective_JJ (_( both_DT 2.3-fold_NN )_) ._SENT As_RB with_IN cisplatin_NN ICLs_NNS ,_, it_PP is_VBZ again_RB striking_JJ that_IN there_EX is_VBZ little_JJ correlation_NN between_IN ability_NN to_TO eliminate_VB the_DT cisplatin_NN lesion_NN ,_, this_DT time_NN the_DT intrastrand_NN cross-link_NN ,_, and_CC cellular_JJ sensitivity_NN amongst_IN NER_JJ mutants_NNS ._SENT The_DT extreme_JJ sensitivity_NN of_IN the_DT ERCC1_NP and_CC XPF_NP cell_NN lines_NNS strongly_RB suggests_VBZ that_IN they_PP have_VBP a_DT dual_JJ deficiency_NN in_IN excision_NN repair_NN and_CC another_DT pathway_NN vital_JJ for_IN the_DT repair_NN and_CC /or_NN tolerance_NN of_IN critical_JJ cisplatin_NN --_: DNA_NP adducts_VBZ ._SENT Importance_NN of_IN homology-driven_JJ recombination_NN in_IN response_NN to_TO cisplatin_NN |_SYM There_EX is_VBZ good_JJ evidence_NN that_IN homologous_JJ recombination_NN plays_VBZ a_DT role_NN in_IN the_DT cellular_JJ response_NN to_TO cisplatin_NN in_IN lower_JJR organisms_NNS (_( ,_, )_) ._SENT Therefore_RB ,_, defects_NNS in_IN recombination_NN as_RB well_RB as_IN NER_NN may_MD account_VB for_IN the_DT extreme_JJ cisplatin_NN hypersensitivity_NN of_IN ERCC1_NP and_CC XPF_NP mammalian_JJ cells_NNS ._SENT XRCC2_NP (_( irs1_JJ )_) and_CC XRCC3_NP (_( irs1SF_NN )_) cells_NNS ,_, defective_JJ for_IN two_CD Rad51-related_JJ recombination_NN factors_NNS ,_, are_VBP derived_VBN from_IN the_DT V79_NP and_CC AA8_NP parent_NN cell_NN lines_NNS ,_, respectively_RB ,_, and_CC xrs5_JJ cells_NNS [_SYM XRCC5_JJ mutant_JJ cells_NNS ,_, defective_JJ in_IN the_DT Ku86_NP protein_NN ,_, required_VBN for_IN non-homologous_JJ end_NN joining_VBG (_( NHEJ_NP )_) ]_SYM are_VBP derived_VBN from_IN CHO-K1_JJ cells_NNS ._SENT The_DT cisplatin_NN sensitivities_NNS of_IN these_DT mutants_NNS ,_, together_RB with_IN their_PP$ parents_NNS ,_, are_VBP shown_VBN in_IN Figure_NP ._SENT Confirming_VBG published_VBN data_NNS ,_, the_DT XRCC2_NP and_CC XRCC3_NP mutants_NNS showed_VBD extreme_JJ sensitivity_NN to_TO cisplatin_NN ,_, having_VBG 50-_CD and_CC 38-fold_JJ higher_JJR sensitivities_NNS compared_VBN to_TO their_PP$ parent_NN cell_NN lines_NNS (_( Fig._NN A_NP and_CC B_NP ,_, respectively_RB )_) ._SENT These_DT values_NNS are_VBP similar_JJ to_TO those_DT obtained_VBN with_IN the_DT XPF_NP and_CC ERCC1_NP cells_NNS ._SENT In_IN contrast_NN ,_, the_DT NHEJ_NP mutant_JJ xrs5_NN showed_VBD only_RB a_DT slight_JJ increase_NN in_IN sensitivity_NN (_( 1.7-fold_NN )_) compared_VBN to_TO the_DT parent_NN cell_NN line_NN ,_, suggesting_VBG that_IN the_DT involvement_NN of_IN the_DT NHEJ_NP pathway_NN in_IN the_DT repair_NN of_IN cisplatin_JJ DNA_NN damage_NN is_VBZ minor_JJ (_( Fig._NN C_NP )_) ._SENT In_IN S.cerevisiae_NP the_DT repair_NN of_IN psoralen-_NN and_CC mechlorethamine-_NN induced_VBN DNA_NP ICLs_NP involves_VBZ the_DT formation_NN of_IN DSBs_NP in_IN replicating_VBG cells_NNS (_( ,_, ,_, )_) ._SENT Similarly_RB ,_, we_PP have_VBP clearly_RB demonstrated_VBN that_IN DSBs_NP also_RB arise_VBP in_IN mammalian_JJ (_( CHO_NP )_) cells_NNS during_IN processing_NN of_IN mechlorethamine-induced_JJ ICLs_NNS ._SENT However_RB ,_, despite_IN these_DT suggestions_NNS ,_, the_DT induction_NN of_IN DSBs_NP during_IN the_DT processing_NN of_IN cisplatin-induced_JJ DNA_NN damage_NN has_VBZ not_RB been_VBN investigated_VBN in_IN detail_NN ._SENT To_TO address_VB this_DT ,_, the_DT induction_NN of_IN DSBs_NP following_VBG cisplatin_NN treatment_NN was_VBD examined_VBN using_VBG PFGE_NP ._SENT Exponentially_RB growing_VBG AA8_NP cells_NNS were_VBD treated_VBN with_IN increasing_VBG doses_NNS of_IN cisplatin_NN for_IN 1_CD h_NN and_CC analysed_VBN by_IN PFGE_NP ._SENT DNA_NN from_IN cells_NNS treated_VBN with_IN an_DT IC50_NP dose_NN (_( 15_CD microM_NN )_) of_IN mechlorethamine_NN (_( nitrogen_NN mustard_NN )_) was_VBD included_VBN as_IN a_DT positive_JJ control_NN ._SENT No_DT DSBs_NP were_VBD observed_VBN following_VBG cisplatin_JJ treatment_NN at_IN 150_CD microM_NN (_( three_CD times_NNS the_DT IC50_NP )_) (_( Fig._NN A_NP )_) ._SENT As_IN expected_VBN ,_, the_DT ICLs_NNS induced_VBN by_IN nitrogen_NN mustard_NN resulted_VBN in_IN the_DT accumulation_NN of_IN DSBs_NP ,_, producing_VBG a_DT lower_RBR molecular_JJ weight_NN smear_NN of_IN DNA_NN released_VBN from_IN the_DT plugs_NNS ._SENT To_TO investigate_VB whether_IN cisplatin_NN DSBs_NNS arise_VBP over_IN longer_JJR times_NNS ,_, AA8_NP cells_NNS were_VBD treated_VBN with_IN 100_CD microM_NN cisplatin_NN for_IN 1_CD h_NN and_CC DSBs_NP were_VBD monitored_VBN over_IN a_DT 0_CD --_: 24_CD h_NN period_NN ._SENT No_DT DSBs_NP were_VBD observed_VBN at_IN any_DT of_IN the_DT time_NN points_NNS analysed_VBN (_( Fig._NN B_NN )_) ._SENT The_DT XRCC2_NP and_CC XRCC3_NP homologous_JJ recombination_NN mutants_NNS are_VBP highly_RB sensitive_JJ to_TO nitrogen_NN mustard_NN and_CC this_DT correlates_NNS with_IN an_DT impaired_JJ ability_NN to_TO repair_VB HN2-induced_NP DSBs_NP ._SENT XRCC2_NP and_CC XRCC3_NP mutants_NNS are_VBP also_RB extremely_RB sensitive_JJ to_TO cisplatin_NN ._SENT If_IN the_DT level_NN of_IN induction_NN of_IN DSBs_NP by_IN cisplatin_NN is_VBZ very_RB low_JJ and_CC if_IN they_PP are_VBP readily_RB repaired_VBN in_IN recombination-proficient_JJ AA8_NP cells_NNS ,_, it_PP is_VBZ possible_JJ that_IN this_DT PFGE_NP approach_NN is_VBZ not_RB sensitive_JJ enough_RB to_TO detect_VB these_DT DSBs_NP ._SENT If_IN the_DT high_JJ sensitivity_NN of_IN XRCC2_NP and_CC XRCC3_NP mutants_NNS to_TO cisplatin_NN is_VBZ associated_VBN with_IN impaired_JJ repair_NN of_IN low_JJ levels_NNS of_IN DSBs_NP ,_, these_DT mutants_NNS should_MD accumulate_VB DSBs_NP following_VBG cisplatin_NN treatment_NN ._SENT To_TO investigate_VB this_DT possibility_NN ,_, the_DT induction_NN of_IN DSBs_NP was_VBD examined_VBN in_IN the_DT wild-type_NN (_( AA8_NP and_CC V79_NP )_) ,_, XRCC2_NP and_CC XRCC3_NP mutants_NNS over_IN a_DT 24_CD h_NN time_NN period_NN ,_, following_VBG 1_CD h_NN treatment_NN with_IN up_IN to_TO 100_CD microM_NN cisplatin_NN ._SENT These_DT experiments_NNS failed_VBD to_TO demonstrate_VB the_DT occurrence_NN of_IN any_DT DSBs_NP (_( data_NN not_RB shown_VBN )_) ._SENT These_DT results_NNS suggest_VBP that_IN DSBs_NNS do_VBP not_RB occur_VB in_IN the_DT processing_NN of_IN cisplatin-induced_JJ DNA_NN damage_NN ,_, in_IN contrast_NN to_TO other_JJ common_JJ agents_NNS that_WDT induce_VBP ICLs_NNS ._SENT Finally_RB ,_, we_PP determined_VBD whether_IN a_DT recombination_NN mutant_NN (_( XRCC3_NP ,_, irs1SF_NP )_) is_VBZ competent_JJ to_TO initiate_VB ICL_NP repair_NN ,_, specifically_RB at_IN the_DT cross-link_NN uncoupling_VBG stage_NN ._SENT Cells_NNS were_VBD treated_VBN with_IN 50_CD microM_NN cisplatin_NN for_IN 1_CD h_NN and_CC ICL_NP uncoupling_VBG followed_VBN during_IN 72_CD h_NN post-treatment_JJ incubation_NN in_IN complete_JJ medium_NN ,_, using_VBG the_DT modified_JJ Comet_NN assay_NN ._SENT XRCC3_JJ cells_NNS were_VBD defective_JJ in_IN the_DT uncoupling_VBG of_IN ICLs_NP (_( Fig._NN C_NP )_) ._SENT This_DT surprising_JJ result_NN indicates_VBZ that_IN the_DT uncoupling_VBG stage_NN of_IN cisplatin_JJ ICL_NP repair_NN might_MD be_VB dependent_JJ upon_IN the_DT formation_NN of_IN early_JJ recombination_NN intermediates_NNS ._SENT This_DT contrasts_VBZ with_IN nitrogen_NN mustard_NN ,_, where_WRB XRCC3-defective_JJ cells_NNS have_VBP been_VBN shown_VBN to_TO be_VB capable_JJ of_IN incising_VBG the_DT ICLs_NNS induced_VBN by_IN this_DT agent_NN ._SENT Figure_NP 1_CD |_SYM Cisplatin_NP sensitivity_NN of_IN parental_JJ AA8_NP cells_NNS and_CC NER_JJ mutants_NNS XPB_NP (_( UV23_NP )_) ,_, XPD_NP (_( UV42_NP )_) ,_, XPF_NP (_( UV47_JJ )_) ,_, ERCC1_NP (_( UV96_NP )_) and_CC XPG_NP (_( UV135_NP )_) ._SENT Cisplatin_JJ sensitivity_NN of_IN parental_JJ AA8_NP cells_NNS and_CC NER_JJ mutants_NNS XPB_NP (_( UV23_NP )_) ,_, XPD_NP (_( UV42_NP )_) ,_, XPF_NP (_( UV47_JJ )_) ,_, ERCC1_NP (_( UV96_NP )_) and_CC XPG_NP (_( UV135_NP )_) ._SENT Exponentially_RB growing_VBG cells_NNS were_VBD treated_VBN with_IN increasing_VBG concentrations_NNS of_IN cisplatin_NN for_IN 1_CD h_NN ,_, incubated_VBN in_IN drug-free_JJ medium_NN for_IN 3_CD days_NNS and_CC stained_VBN with_IN SRB_NP ._SENT Fraction_NN of_IN growth_NN inhibition_NN was_VBD calculated_VBN for_IN each_DT dose_NN as_IN described_VBN in_IN Materials_NPS and_CC Methods_NP ._SENT All_DT results_NNS are_VBP the_DT means_NNS of_IN at_IN least_JJS three_CD independent_JJ experiments_NNS and_CC error_NN bars_NNS show_VBP the_DT standard_JJ error_NN of_IN the_DT mean_NN ._SENT Figure_NP 2_CD |_SYM (_( A_NP )_) Decrease_NP in_IN comet_NN tail_NN moment_NN (_( TM_NP )_) with_IN increasing_VBG concentration_NN of_IN cisplatin_NN ._SENT (_( A_NP )_) Decrease_NP in_IN comet_NN tail_NN moment_NN (_( TM_NP )_) with_IN increasing_VBG concentration_NN of_IN cisplatin_NN ._SENT AA8_NN cells_NNS were_VBD treated_VBN with_IN increasing_VBG doses_NNS of_IN cisplatin_NN for_IN 1_CD h_NN and_CC analysed_VBD immediately_RB ._SENT For_IN each_DT drug_NN concentration_NN ,_, the_DT TM_NP of_IN 50_CD comets_NNS was_VBD measured_VBN and_CC the_DT mean_JJ values_NNS were_VBD calculated_VBN ._SENT The_DT percentage_NN decrease_NN in_IN TM_NP in_IN comparison_NN with_IN untreated_JJ samples_NNS was_VBD then_RB calculated_JJ (_( Materials_NNS and_CC Methods_NNS )_) ._SENT The_DT results_NNS shown_VBN above_IN are_VBP the_DT means_NN of_IN three_CD independent_JJ experiments_NNS and_CC error_NN bars_NNS show_VBP the_DT standard_JJ error_NN of_IN the_DT mean_NN ._SENT (_( B_LS )_) The_DT early_JJ repair_NN kinetics_NNS of_IN ICL_NP repair_NN in_IN AA8_NP cells_NNS treated_VBN with_IN 50_CD microM_NN cisplatin_NN for_IN 1_CD h_NN and_CC samples_NNS removed_VBN at_IN increasing_VBG times_NNS for_IN Comet_NP analysis_NN ._SENT The_DT results_NNS presented_VBN are_VBP the_DT means_NNS of_IN at_IN least_JJS three_CD independent_JJ experiments_NNS and_CC error_NN bars_NNS show_VBP the_DT standard_JJ error_NN of_IN the_DT mean_NN ._SENT (_( C_NP )_) Induction_NN and_CC repair_NN of_IN cisplatin_JJ ICLs_NNS in_IN parental_JJ and_CC NER_JJ mutant_JJ cell_NN lines_NNS ._SENT WT_NP (_( AA8_NP )_) ,_, XPB_NP (_( UV23_NP )_) ,_, XPG_NP (_( UV135_NP )_) ,_, XPF_NP (_( UV47_JJ )_) and_CC ERCC1_NP (_( UV96_NP )_) cells_NNS were_VBD treated_VBN with_IN 50_CD microM_NN cisplatin_NN for_IN 1_CD h_NN and_CC incubated_VBN in_IN drug-free_JJ medium_NN for_IN 24_CD ,_, 48_CD and_CC 72_CD h_NN to_TO allow_VB repair_NN ._SENT Percentage_NN decrease_NN in_IN TM_NP in_IN comparison_NN with_IN untreated_JJ samples_NNS was_VBD calculated_VBN as_RB above_RB ._SENT The_DT results_NNS presented_VBN are_VBP the_DT means_NNS of_IN at_IN least_JJS three_CD independent_JJ experiments_NNS and_CC error_NN bars_NNS show_VBP the_DT standard_JJ error_NN of_IN the_DT mean_NN ._SENT Figure_NP 3_CD |_SYM (_( A_NP )_) Induction_NN of_IN cisplatin_JJ intrastrand_NN cross-links_NNS following_VBG treatment_NN of_IN AA8_NP cells_NNS with_IN increasing_VBG doses_NNS of_IN cisplatin_NN ._SENT (_( A_NP )_) Induction_NN of_IN cisplatin_JJ intrastrand_NN cross-links_NNS following_VBG treatment_NN of_IN AA8_NP cells_NNS with_IN increasing_VBG doses_NNS of_IN cisplatin_NN ._SENT Exponentially_RB growing_VBG AA8_NP cells_NNS were_VBD treated_VBN with_IN cisplatin_NN for_IN 1_CD h_NN and_CC the_DT level_NN of_IN intrastrand_NP adducts_VBZ were_VBD analysed_VBN immediately_RB using_VBG competitive_JJ ELISA_NP ._SENT (_( B_NP )_) Kinetics_NP of_IN cisplatin_NN intrastrand_NN adduct_VBP removal_NN in_IN AA8_NP cells_NNS ._SENT Exponentially_RB growing_VBG AA8_NP cells_NNS were_VBD treated_VBN with_IN 50_CD microM_NN cisplatin_NN for_IN 1_CD h_NN ,_, incubated_VBN in_IN drug-free_JJ medium_NN for_IN the_DT stated_JJ times_NNS and_CC the_DT level_NN of_IN intrastrand_NN adducts_VBZ quantified_VBN using_VBG competitive_JJ ELISA_NP ._SENT The_DT results_NNS are_VBP the_DT means_NN of_IN five_CD independent_JJ experiments_NNS and_CC the_DT error_NN bars_NNS show_VBP the_DT standard_JJ error_NN of_IN the_DT mean_NN ._SENT Figure_NP 4_CD |_SYM Elimination_NN of_IN cisplatin_JJ intrastrand_NN cross-links_NNS in_IN wild-type_NN (_( AA8_NP )_) cells_NNS and_CC NER_JJ mutants_NNS XPG_NP (_( UV135_NP )_) ,_, XPF_NP (_( UV47_JJ )_) and_CC ERCC1_NP (_( UV96_NP )_) ._SENT Elimination_NN of_IN cisplatin_JJ intrastrand_NN cross-links_NNS in_IN wild-type_NN (_( AA8_NP )_) cells_NNS and_CC NER_JJ mutants_NNS XPG_NP (_( UV135_NP )_) ,_, XPF_NP (_( UV47_JJ )_) and_CC ERCC1_NP (_( UV96_NP )_) ._SENT Cells_NNS were_VBD treated_VBN with_IN 50_CD microM_NN cisplatin_NN for_IN 1_CD h_NN and_CC adduct_VB levels_NNS quantified_VBN immediately_RB following_VBG drug_NN removal_NN (_( 0_CD h_NN )_) and_CC 24_CD and_CC 48_CD h_NN later_RBR using_VBG competitive_JJ ELISA_NP ._SENT The_DT results_NNS presented_VBN are_VBP the_DT means_NNS of_IN between_IN three_CD and_CC five_CD individual_JJ experiments_NNS and_CC error_NN bars_NNS are_VBP the_DT standard_JJ error_NN of_IN the_DT mean_NN ._SENT Figure_NP 5_CD |_SYM Cisplatin_NP sensitivity_NN of_IN CHO_NP recombination_NN mutants_NNS ._SENT Cisplatin_JJ sensitivity_NN of_IN CHO_NP recombination_NN mutants_NNS ._SENT (_( A_NP )_) XRCC2_NP (_( irs1_JJ )_) and_CC its_PP$ parental_JJ cell_NN line_NN V79_NN ;_: (_( B_NP )_) XRCC3_NP (_( irs1SF_NN )_) and_CC parental_JJ AA8_JJ cells_NNS ;_: (_( C_NP )_) the_DT NHEJ_NP mutant_NN XRCC5_NP (_( xrs5_NN )_) and_CC its_PP$ parental_JJ cell_NN line_NN CHO-K1_NP ._SENT Cells_NNS were_VBD treated_VBN with_IN increasing_VBG concentrations_NNS of_IN cisplatin_NN for_IN 1_CD h_NN ,_, incubated_VBN in_IN drug-free_JJ medium_NN for_IN 3_CD days_NNS and_CC stained_VBN with_IN SRB_NP ._SENT All_DT results_NNS are_VBP the_DT means_NNS of_IN at_IN least_JJS three_CD independent_JJ experiments_NNS and_CC error_NN bars_NNS are_VBP the_DT standard_JJ error_NN of_IN the_DT mean_NN ._SENT Figure_NP 6_CD |_SYM (_( A_NP )_) PFGE_NP analysis_NN of_IN DNA_NN from_IN cells_NNS treated_VBN with_IN increasing_VBG doses_NNS of_IN cisplatin_NN ._SENT (_( A_NP )_) PFGE_NP analysis_NN of_IN DNA_NN from_IN cells_NNS treated_VBN with_IN increasing_VBG doses_NNS of_IN cisplatin_NN ._SENT Exponentially_RB growing_VBG AA8_NP cells_NNS were_VBD treated_VBN with_IN the_DT stated_JJ concentrations_NNS of_IN cisplatin_NN or_CC 15_CD microM_NN nitrogen_NN mustard_NN for_IN 1_CD h_NN and_CC immediately_RB analysed_VBN for_IN the_DT presence_NN of_IN DSBs_NP on_IN pulsed_VBN field_NN gels_NNS ._SENT (_( B_NP )_) PFGE_NP analysis_NN of_IN DNA_NN from_IN cisplatin-treated_JJ cells_NNS subject_JJ to_TO further_RBR post-treatment_JJ incubation_NN ._SENT Exponentially_RB growing_VBG AA8_NP cells_NNS were_VBD treated_VBN with_IN 100_CD microM_NN cisplatin_NN for_IN 1_CD h_NN and_CC incubated_VBN in_IN drug-free_JJ medium_NN for_IN the_DT stated_JJ time_NN prior_RB to_TO PFGE_NP analysis_NN ._SENT Lane_NP C_NP contained_VBD DNA_NN from_IN mock-_NN treated_VBN cells_NNS subject_JJ to_TO 24_CD h_NN post-treatment_JJ incubation_NN ._SENT (_( C_NP )_) ICL_NP uncoupling_VBG in_IN recombination-defective_JJ cells_NNS ._SENT irs1SF_NP (_( XRCC3_NP mutant_NN )_) cells_NNS and_CC their_PP$ isogenic_JJ parent_NN AA8_NP were_VBD treated_VBN with_IN 50_CD microM_NN cisplatin_NN for_IN 1_CD h_NN and_CC incubated_VBN in_IN drug-free_JJ medium_NN for_IN 24_CD ,_, 48_CD and_CC 72_CD h_NN to_TO allow_VB repair_NN ._SENT Percentage_NN decrease_NN in_IN TM_NP in_IN comparison_NN with_IN untreated_JJ samples_NNS was_VBD calculated_VBN as_RB above_RB ._SENT The_DT results_NNS presented_VBN are_VBP the_DT means_NNS of_IN at_IN least_JJS three_CD independent_JJ experiments_NNS and_CC error_NN bars_NNS show_VBP the_DT standard_JJ error_NN of_IN the_DT mean_NN ._SENT It_PP has_VBZ been_VBN established_VBN that_IN both_DT NER_JJ and_CC homology-driven_JJ recombination_NN activities_NNS are_VBP important_JJ for_IN the_DT elimination_NN of_IN cisplatin_NN DNA_NN adducts_VBZ in_IN Escherichia_NP coli_NNS (_( ,_, )_) and_CC yeast_NN (_( ,_, )_) cells_NNS ._SENT In_IN agreement_NN with_IN previous_JJ reports_NNS (_( ,_, )_) ,_, the_DT results_NNS obtained_VBN in_IN this_DT study_NN confirm_VBP that_IN XPF-_NP and_CC ERCC1-defective_JJ mammalian_JJ cells_NNS are_VBP extremely_RB sensitive_JJ to_TO cisplatin_NN ._SENT In_IN contrast_NN ,_, the_DT other_JJ NER_NN mutants_NNS considered_VBN here_RB (_( XPB_NP ,_, XPD_NP ,_, XPG_NP and_CC CSB_NP )_) do_VBP not_RB possess_VB this_DT extreme_JJ sensitivity_NN ._SENT This_DT implies_VBZ that_IN the_DT XPF_NP --_: ERCC1_JJ structure-specific_JJ nuclease_NN plays_VBZ a_DT key_JJ role_NN in_IN the_DT repair_NN of_IN critical_JJ cisplatin_NN lesions_NNS or_CC repair_NN intermediates_NNS ._SENT To_TO address_VB whether_IN the_DT excision_NN repair_NN of_IN a_DT particular_JJ lesion_NN is_VBZ specifically_RB reduced_VBN or_CC absent_JJ in_IN XPF-_NP and_CC ERCC1-defective_JJ cells_NNS we_PP have_VBP measured_VBN the_DT capacity_NN of_IN a_DT set_NN of_IN NER_JJ mutants_NNS to_TO eliminate_VB two_CD cisplatin_NN adducts_VBZ which_WDT constitute_VBP critical_JJ DNA_NN damage_NN induced_VBN by_IN this_DT agent_NN ;_: the_DT ICL_NP and_CC 1,2-intrastrand_NP cross-link_NN ._SENT Both_CC the_DT highly_RB sensitive_JJ XPF_NP and_CC ERCC1_NP mutants_NNS and_CC the_DT slightly_RB sensitive_JJ XPB_NP and_CC XPG_NP mutants_NNS were_VBD defective_JJ in_IN the_DT uncoupling_VBG of_IN ICLs_NNS ,_, indicating_VBG that_IN a_DT full_JJ complement_NN of_IN NER_JJ proteins_NNS is_VBZ required_VBN for_IN the_DT excision_NN of_IN cisplatin_NN ICLs_NNS ._SENT No_DT clear_JJ correlation_NN was_VBD observed_VBN between_IN cellular_JJ sensitivity_NN and_CC ICL_NP uncoupling_VBG capacity_NN ._SENT Although_IN the_DT XPB_NP and_CC XPG_NP mutants_NNS were_VBD completely_RB defective_JJ in_IN the_DT uncoupling_VBG step_NN of_IN ICL_NP repair_NN ,_, they_PP were_VBD only_RB 1.4-_CD and_CC 3.1-fold_JJ more_JJR sensitive_JJ to_TO cisplatin_NN than_IN the_DT parent_NN cell_NN line_NN ,_, compared_VBN to_TO a_DT 37_CD --_: 40-fold_JJ increase_NN in_IN sensitivity_NN observed_VBN in_IN XPF_NP and_CC ERCC1_NP mutants_NNS ._SENT Meyn_NP et_FW al._FW demonstrated_VBD that_IN another_DT ERCC1_JJ mutant_JJ CHO_NP cell_NN line_NN ,_, UV20_NP ,_, was_VBD extremely_RB sensitive_JJ to_TO cisplatin_NN and_CC defective_JJ in_IN the_DT uncoupling_VBG of_IN interstrand_NN cross-links_NNS ,_, and_CC this_DT was_VBD taken_VBN to_TO demonstrate_VB a_DT direct_JJ relationship_NN between_IN sensitivity_NN and_CC ICL_NP repair_NN ._SENT However_RB ,_, the_DT ICL_NP repair_NN capacity_NN of_IN the_DT less_RBR sensitive_JJ NER-defective_JJ cell_NN lines_NNS was_VBD not_RB investigated_VBN ._SENT Here_RB ,_, for_IN the_DT first_JJ time_NN ,_, we_PP show_VBP that_IN ,_, in_IN addition_NN to_TO XPF_NP --_: ERCC1_NP ,_, other_JJ components_NNS of_IN the_DT NER_JJ machinery_NN are_VBP essential_JJ for_IN the_DT excision_NN of_IN cisplatin_JJ ICLs_NNS in_IN vivo_RB ._SENT The_DT data_NNS suggest_VBP that_IN ICLs_NNS are_VBP not_RB ,_, by_IN themselves_PP ,_, the_DT critical_JJ DNA_NN lesion_NN induced_VBN by_IN cisplatin_NN since_IN an_DT inability_NN to_TO repair_VB this_DT lesion_NN only_RB leads_VBZ to_TO a_DT very_RB modest_JJ increase_NN in_IN cellular_JJ sensitivity_NN ._SENT These_DT results_NNS are_VBP very_RB different_JJ from_IN those_DT obtained_VBN with_IN nitrogen_NN mustard_NN ,_, where_WRB a_DT direct_JJ correlation_NN between_IN mutant_JJ sensitivity_NN and_CC the_DT ability_NN to_TO uncouple_VB ICLs_NNS was_VBD evident_JJ ._SENT In_IN this_DT case_NN the_DT XPB_NP and_CC XPG_NP cells_NNS were_VBD only_RB slightly_RB drug_NN sensitive_JJ and_CC were_VBD proficient_JJ in_IN the_DT uncoupling_VBG of_IN nitrogen_NN mustard-induced_JJ ICLs_NNS ,_, whereas_IN the_DT highly_RB sensitive_JJ XPF_NP and_CC ERCC1_NP cells_NNS were_VBD severely_RB defective_JJ ._SENT In_IN addition_NN ,_, recent_JJ biochemical_JJ studies_NNS employing_VBG purified_VBN proteins_NNS (_( ,_, )_) have_VBP shown_VBN that_IN the_DT uncoupling_VBG step_NN of_IN psoralen_NP ICL_NP repair_NN can_MD be_VB achieved_VBN by_IN the_DT XPF_NP --_: ERCC1_JJ nuclease_NN in_IN the_DT absence_NN of_IN other_JJ factors_NNS (_( except_IN RPA_NP in_IN the_DT former_JJ study_NN )_) ._SENT A_DT further_RBR cross-link-specific_JJ excision_NN reaction_NN has_VBZ been_VBN identified_VBN by_IN Bessho_NP et_FW al._FW ._SENT Here_RB the_DT complete_JJ human_JJ excision_NN nuclease_NN makes_VBZ dual_JJ incisions_NNS 5_CD '_'' to_TO a_DT psoralen_JJ cross-link_NN on_IN one_CD strand_NN of_IN the_DT damaged_JJ DNA_NN only_RB ._SENT Although_IN the_DT authors_NNS state_VBP that_IN this_DT intermediate_NN might_MD act_VB as_IN an_DT initiation_NN signal_NN for_IN recombination_NN ,_, such_PDT a_DT reaction_NN does_VBZ not_RB release_VB the_DT cross-link_NN and_CC therefore_RB probably_RB does_VBZ not_RB represent_VB the_DT uncoupling_VBG reactions_NNS seen_VBN in_IN our_PP$ study_NN ._SENT Further_RBR biochemical_JJ studies_NNS employing_VBG defined_VBN cisplatin_NN ICL-containing_NN substrates_NNS are_VBP required_VBN to_TO elucidate_VB the_DT molecular_JJ nature_NN of_IN this_DT reaction_NN ._SENT A_DT surprising_JJ observation_NN was_VBD that_IN the_DT XRCC2_NP and_CC XRCC3_NP mutants_NNS were_VBD unable_JJ to_TO uncouple_VB the_DT cisplatin_JJ ICLs_NNS (_( Fig._NN C_NP )_) ._SENT This_DT raises_VBZ the_DT possibility_NN that_IN homologous_JJ recombination_NN is_VBZ initiated_VBN prior_RB to_TO the_DT incisions_NNS which_WDT uncouple_VBP the_DT cisplatin_NN cross-link_NN and_CC that_IN the_DT incision_NN reactions_NNS depend_VBP upon_IN an_DT early_JJ recombination_NN intermediate_NN being_VBG formed_VBN ._SENT Perhaps_RB a_DT homology_NN search_NN ,_, requiring_VBG the_DT Rad51_JJ family_NN of_IN proteins_NNS (_( which_WDT includes_VBZ Xrcc2_NP and_CC Xrcc3_NP 